尽管有Pemgarda COVID风险降低数据，Invivyd仍下跌18%

2024-08-28 00:59

Patients treated with Invivyd's (NASDAQ:IVVD) Pemgarda (pemibivart) showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo in a phase 3 trial.
In a group of all-comer immunocompetent individuals, 1.9% of treated individuals in a 180-day time period developed symptomatic COVID. compared to 11.9% in the placebo group.
Pemgarda currently has Emergency Use Authorization from the U.S. FDA for COVID pre-exposure prophylaxis.
Despite the results, shares are off 18%.

More on Invivyd